| 81 | 0 | 50 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨非小细胞肺癌(NSCLC)患者癌组织三结构域蛋白16(TRIM16)、转化生长因子β受体2(TGFBR2)表达及与临床病理特征、预后的关系。方法 收集河北省沧州市中心医院2020年1月至2021年12月行手术治疗的84例NSCLC患者癌组织及癌旁组织，采用免疫组织化学法检测TRIM16、TGFBR2蛋白表达，同时收集整理病理类型、淋巴结转移、肿瘤分期等临床资料；采用Spearman法分析相关性；采用Kaplan-Meier法分析TRIM16、TGFBR2与患者预后的关系；采用COX回归分析患者预后的影响因素。结果 与癌旁正常组织相比，NSCLC组织中TRIM16、TGFBR2阳性率明显较低(P<0.05);TRIM16、TGFBR2表达与TNM分期、淋巴结转移、细胞分化程度有关(P<0.05)。肿瘤直径>3 cm的NSCLC患者TRIM16阳性表达比例显著低于肿瘤直径≤3 cm的NSCLC患者(P<0.05)。浸润深度为深层的NSCLC患者TGFBR2阳性表达比例显著低于浸润深度为浅层的NSCLC患者(P<0.05);NSCLC组织TRIM16与TGFBR2表达呈正相关(r=0.440,P<0.05);TRIM16、TGFBR2阳性表达患者3年生存率高于TRIM16、TGFBR2阴性表达患者(Log rankχ2=16.476、8.862,P<0.05)。TNM分期、淋巴结转移是NSCLC患者死亡的危险因素，TRIM16、TGFBR2是保护因素(P<0.05)。结论 NSCLC组织TRIM16、TGFBR2表达与患者临床病理特征及预后有密切联系。
Abstract：Objective To explore the expression of tripartite motif protein 16(TRIM16) and transforming growth factor β receptor 2(TGFBR2) in cancer tissues of non-small cell lung cancer(NSCLC) patients, and their relationship with clinicopathological characteristics and prognosis. Methods Cancer tissues and adjacent non-tumor tissues from 84 NSCLC patients who underwent surgical treatment at Cangzhou Central Hospital, Hebei Province from January 2020 to December 2021 were collected. Immunohistochemistry was performed to detect the protein expression of TRIM16 and TGFBR2. Meanwhile, clinical data such as pathological type, lymph node metastasis, and tumor staging were collected. Spearman's rank correlation analysis was applied to evaluate the correlation between TRIM16 and TGFBR2 expression. Kaplan-Meier method was applied to analyze the relationship between the expression of TRIM16 and TGFBR2 in NSCLC tissues and prognosis of patients. Cox proportional hazards regression model was used to identify the prognostic factors for NSCLC patients. Results The positive rates of TRIM16 and TGFBR2 in NSCLC tissues were significantly lower than those in adjacent non-tumor tissues(P < 0.05). The expression levels of TRIM16 and TGFBR2 were correlated with TNM stage, lymph node metastasis and cell differentiation(P < 0.05). The positive rate of TRIM16 was significantly lower in NSCLC patients with tumor diameter> 3 cm than those with tumor diameter ≤ 3 cm(P < 0.05). The positive rate of TGFBR2 was significantly lower in NSCLC patients with deep invasion than in those with superficial invasion(P < 0.05). There was a positive correlation between TRIM16 and TGFBR2 expression in NSCLC tissues(r=0.440, P < 0.05). The three-year survival rate was significantly higher in patients with positive TRIM16 or TGFBR2 expression than those with negative expression(Log rank χ2=16.476 and 8.862, respectively; P < 0.05). TNM stage and lymph node metastasis were risk factors for death in NSCLC patients, while TRIM16 and TGFBR2 were protective factors(P < 0.05). Conclusion The expression of TRIM16 and TGFBR2 in NSCLC tissues is closely related to the clinicopathological characteristics and prognosis of patients.
[1]Xu FZ, Meng FR, Li WJ, et al. Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy[J]. Open Life Sci, 2024, 19(1):20220923.DOI:10. 1515/olst-2022-0923.
[2]陈丽娥,王识华,洪湘,等.非小细胞肺癌患者PD-L1表达水平与临床病理特征及细胞免疫的关系[J].中国医师杂志, 2020, 22(8):39-44. DOI:10. 3969/j. issn. 1002-1701. 2021. 06. 071.
[3]Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent[J]. J Clin Oncol, 2022, 40(6):567-575. DOI:10. 1200/JCO. 21.01929.
[4]Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med, 2021, 27(8):1345-1356. DOI:10. 1200/JCO. 21. 01285.
[5]倪晨明,郑楷炼,潘亚奇,等.三结构域蛋白14在胰腺癌组织中的表达及其与临床病理特征和预后的关系[J].中华胰腺病杂志,2020, 20(2):137-141. DOI:10. 3760/cma. j. cn115667-20190812-00069.
[6]Ding YX, Lu YY, Guo J, et al. An investigation of the molecular characterization of the tripartite motif(TRIM)family and primary validation of TRIM31 in gastric cancer[J]. Hum Genomics, 2024, 18(1):77.DOI:10. 1186/s40246-024-00563-7.
[7]Huang N, Sun X, Li P, et al. TRIM family contribute to tumorigenesis, cancer development, and drug resistance[J]. Exp Hematol Oncol,2022, 11(1):75. DOI:10. 1186/s40164-022-00317-5.
[8]Ruan L, Liu W, Yang Y, et al. TRIM16 overexpression inhibits the metastasis of colorectal cancer through mediating snail degradation[J].Exp Cell Res, 2021, 406(1):112735. DOI:10. 1016/j. yexcr. 2021.112735.
[9]Teicher BA. TGFβ-directed therapeutics:2020[J]. Pharmacol Ther,2021, 217:107666. DOI:10. 1016/j. pharmthera. 2020. 107666.
[10]Fang Z, Zhang N, Yuan X, et al. GABPA-activated TGFBR2 transcription inhibits aggressiveness but is epigenetically erased by oncometabolites in renal cell carcinoma[J]. J Exp Clin Cancer Res,2022, 41(1):173. DOI:10. 1186/s13046-022-02425-3.
[11]Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura:Advances Since the 2015 Classification[J]. J Thorac Oncol, 2022, 17(5):608-622. DOI:10. 1016/j. jtho. 2021.09. 012.
[12]马群,马磊.非小细胞肺癌患者肿瘤组织PD-1和PD-L1与临床病理参数和预后的关系[J].四川生理科学杂志, 2021, 43(4):549-552.
[13]Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer:Current status and perspectives[J]. Crit Rev Oncol Hematol, 2021, 157:103194. DOI:10.1016/j. critrevonc. 2021. 103194.
[14]贾俊斌,顾岩.非小细胞肺癌来源外泌体的免疫效应和潜在生物标志物[J].临床肺科杂志, 2022, 27(8):1265-1269. DOI:10. 3969/j.issn. 1009-6663. 2022. 08. 028.
[15]杜进臣,聂洪鑫,胡尕伟,等.长链非编码RNA ZEB2-AS1在非小细胞肺癌中的表达及临床病理特征与预后的关系[J].医学研究杂志, 2022, 51(1):60-64. DOI:10. 11969/j. issn. 1673-548X. 2022. 01.015.
[16]Wu G, Xu Y, Li L, et al. Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinoma[J]. Int J Med Sci,2020, 17(18):2905-2916. DOI:10. 11969/j. issn. 1673-548X. 2022. 01.015.
[17]阮龙辉,褚智杰,杨成,等. TRIM16在结直肠癌中的表达及对细胞迁移和侵袭的影响[J].临床和实验医学杂志, 2022, 21(9):925-930.DOI:10. 3969/j. issn. 1671-4695. 2022. 09. 008.
[18]Xie TT, Tan MH, Gao Y, et al. CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression[J]. Environ Toxicol, 2022, 37(8):1957-1967. DOI:10. 1002/tox. 23437.
[19]Li Q, Chen K, Dong R, et al. LncRNA CASC2 inhibits autophagy and promotes apoptosis in non-small cell lung cancer cells via regulating the miR-214/TRIM16 axis[J]. RSC Adv, 2018, 8(71):40846-40855.DOI:10. 1039/C8RA06360A.
[20]边红芝,韩俊垒,胡建平,等. miR-181c-5p靶向TRIM71调控非小细胞肺癌细胞A549的凋亡研究[J].实用癌症杂志, 2022, 37(1):16-21. DOI:10. 3969/j. issn. 1001-5930. 2022. 01. 004.
[21]宋婷婷,张会芳,韩玉贞.乳腺原发癌和淋巴结转移癌中ALDH1A1和TGF-β1的表达及预后价值[J].滨州医学院学报, 2021,44(1):34-38. DOI:10. 19739/j. cnki. issn1001-9510. 2021. 01. 007.
[22]孟琛,闫冰,王阳,等.转化生长因子β影响上皮细胞和成纤维细胞相互作用的转录组分析[J].中国耳鼻咽喉头颈外科, 2023, 30(8):506-509. DOI:10. 16066/j. 1672-7002. 2023. 08. 007.
[23]Liu M, Kuo F, Capistrano KJ, et al. TGF-β suppresses type 2 immunity to cancer[J]. Nature, 2020, 587(7832):115-120. DOI:10. 1038/s41586-020-2872-x.
[24]胡玉洁,涂红勤,曾洁,等. lncRNA CKMT2-AS1靶向miR-17-5p/TGFBR2分子轴调控子宫颈癌细胞的生物学行为[J].临床与实验病理学杂志, 2022, 38(5):520-525. DOI:10. 16066/j. 1672-7002. 2023.08. 007.
[25]Lo sardo F, Pulito C, Sacconi A, et al. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer[J]. Cancer Lett, 2021, 500:51-63. DOI:10. 1016/j. canlet.2020. 11. 018.
[26]Fan D, Yang Y, Zhang W. A novel circ_MACF1/miR-942-5p/TGFBR2 axis regulates the functional behaviors and drug sensitivity in gefitinib-resistant non-small cell lung cancer cells[J]. BMC Pulmonary Medicine, 2022, 22(1):1-15. DOI:10. 1186/s12890-022-01752-5.
[27]Wu W, Yang J, Yu T, et al. The Role and Mechanism of TRIM Proteins in Gastric Cancer[J]. Cells, 2024, 13(24):2107. DOI:10. 3390/cells13242107.
基本信息:
中图分类号:R734.2
引用信息:
[1]迟玮,张连勇,李静静,等.非小细胞肺癌患者癌组织TRIM16、TGFBR2表达及与临床病理特征、预后的关系分析[J].诊断病理学杂志,2026,33(02):164-169.
基金信息:
沧州市重点研发计划项目（编号：204106180）
2026-02-27
2026-02-27